Jocelyn Dupuy’s Post

For over a decade, Applied StemCell has been a trusted partner to scientists, expanding what you can accomplish through iPSCs. Our human iPSC lines are consistently generated and rigorously characterized, providing you with robust tools to advance your disease research, drug discovery studies, and cell-based medicine development. We understand that as a researcher, you need reliability and reproducibility. That’s why our iPSC lines are: - Pluripotency-Validated: Ensuring differentiation potential across all three germ layers. - Genetically Stable: Thoroughly tested to maintain integrity across passages. - Customizable: Tailored to meet the specific demands of your experimental design, including disease-relevant mutations and reporter lines. Whether you're modeling complex diseases or optimizing cell therapy approaches, our iPSCs are the high-quality foundation you need to produce. Join your peers who trust Applied StemCell to deliver the tools they need for cutting-edge discoveries. 👉 Explore our iPSC catalog and custom services: https://lnkd.in/gm3Gi3qF #iPSCResearch #StemCellModels #PhDResearch #DiseaseModeling #RegenerativeMedicine

Exciting Development in Multiple Myeloma Treatment! 🌟 Johnson & Johnson has just revealed promising results from their Phase III CARTITUDE-4 trial for CARVYKTI (ciltacabtagene autoleucel). This cell therapy shows a significant improvement in overall survival rates for multiple myeloma patients, a true game-changer in the field. The trial compared CARVYKTI with standard therapies and found remarkable results. Patients treated with CARVYKTI had a 76% overall survival rate compared to 64% with standard treatments, and the therapy reduced mortality risk by 45%. These figures demonstrate the potential for CARVYKTI to be a cornerstone treatment for patients with relapsed or refractory multiple myeloma. #LifeSciences #Biotech #ClinicalResearch #J&J #MultipleMyelomaTreatment #Biotechnology #ClinicalTrials #LifeScience #StaffingPartner #ElixirAssociates

SDBN Feed: New brain-mapping tool may be the “START” of next-generation therapeutics https://lnkd.in/djuRMhXN LA JOLLA—Scientists at the Salk Institute are unveiling a new brain-mapping neurotechnology called Single Transcriptome Assisted Rabies Tracing (START). The cutting-edge tool combines two advanced technologies—monosynaptic rabies virus tracing and single-cell transcriptomics—to map the brain’s [...]

📢Breakthrough Collaboration: Lonza and NeuroSense Therapeutics Revolutionize Neurodegeneration Research 🔬 NeuroSense Therapeutics Ltd has entered into a collaboration with Lonza AG to advance theranostics in neurodegeneration. 🧪 The collaboration will focus on identifying exosome-based biomarkers for early diagnosis and treatment. 💡 NeuroSense's lead candidate for ALS, Prime C, has shown promising results in Phase IIb studies. 🤝 The partnership will leverage Lonza's expertise in extracellular vesicles to develop methods for measuring biomarkers. 🧠 #BioprocessUpdates #LonzaAG #NeuroSenseTherapeutics #R&Dcollaboration #neurodegeneration #theranostics #exosome #biomarkers #earlydiagnosis #treatment #ALS #PrimeC #PhaseIIb #extracellularvesicles #measuringbiomarkers #researchanddevelopment ▷ Read the full article here: 📎 https://lnkd.in/dJxbcNcG

Global Database of Exosome Companies, 2024 - https://lnkd.in/ezHg2Pc Exosomes are small vesicles ranging from 30-100nm in size that are found in nearly all eukaryotic fluids and facilitate a range of important cellular functions. They transfer DNA, RNA, and proteins to other cells, thereby altering the function of the targeted cells. In recent years, exosomes have been gaining momentum as a strategy for accessing the therapeutic effects of cells without the risks and difficulties of administering the cells to patients. With at least 27,506 scientific articles published about exosomes and 312 clinical trials underway, these small vesicles have intriguing potential to be used within a range of therapeutic applications. The database features all known companies who are developing exosome and extracellular vesicle (EV) therapies, diagnostics, and platform technologies. #exosomes #extracellularvesicles #advancedtherapies

[FLASH SALE] Global Database of Exosome Companies, 2024 - https://lnkd.in/ezHg2Pc Exosomes are small vesicles ranging from 30-100nm in size that are found in nearly all eukaryotic fluids and facilitate a range of important cellular functions. They transfer DNA, RNA, and proteins to other cells, thereby altering the function of the targeted cells. In recent years, exosomes have been gaining momentum as a strategy for accessing the therapeutic effects of cells without the risks and difficulties of administering the cells to patients. With at least 33,886 scientific articles published about exosomes and at least 403 clinical trials, these small vesicles have intriguing potential to be used across a range of therapeutic applications. The database features all known companies who are developing exosome and extracellular vesicle (EV) therapies, diagnostics, and platform technologies. #exosomes #extracellularvesicles #advancedtherapies

MicroRNA (miRNA) is a class of non-coding single-stranded RNA molecules with a length of about 22 nucleotides encoded by endogenous genes. They play an important role in the process of cell differentiation, biological development, and disease development. With in-depth research on the mechanism of miRNA, miRNA is expected to provide new ideas for diagnosis and drug discovery and development. #MicroRNA #miRNA #RNAsynthesis #syntheticbiology #Biotech

Comparing activation methods to yield clinical-scale expansion of γδ #Tcells Some #Tcelltherapies have been approved to treat patients with conditions like #Bcellmalignancies and #multiplemyeloma, but their use for #solidtumors remains challenging. Gamma delta (γδ) T cells have the inherent ability to infiltrate solid tumors and kill transformed cells, but their low prevalence in peripheral blood poses a challenge when generating enough cells to produce a clinical dose. Next month, Lonza Bioscience Solutions’ Chengkang Zhang (Associate Director, R&D) will present two novel methods for the expansion of #gammadeltaTcells from peripheral blood #mononuclearcells (PBMCs) and present data showcasing their suitability for clinical applications Register for this upcoming #webinar below:

MicroRNA (miRNA) is a class of non-coding single-stranded RNA molecules with a length of about 22 nucleotides encoded by endogenous genes. They play an important role in the process of cell differentiation, biological development, and disease development. With in-depth research on the mechanism of miRNA, miRNA is expected to provide new ideas for diagnosis and drug discovery and development. GenCefe's experienced oligo synthesis technology team has developed various miRNA mimics for gain-of-function studies and inhibitors for loss-of-function studies, with different options for both in vitro and in vivo experiments. Get a free quote NOW: oligo@gencefebio.com #rnasynthesis #miRNA #microRNA #miRNAinhibitor #miRNAmimic

MicroRNA (miRNA) is a class of non-coding single-stranded RNA molecules with a length of about 22 nucleotides encoded by endogenous genes. They play an important role in the process of cell differentiation, biological development, and disease development. With in-depth research on the mechanism of miRNA, miRNA is expected to provide new ideas for diagnosis and drug discovery and development. GenCefe's experienced oligo synthesis technology team has developed various miRNA mimics for gain-of-function studies and inhibitors for loss-of-function studies, with different options for both in vitro and in vivo experiments. Get a free quote NOW: oligo@gencefebio.com #rnasynthesis #miRNA #microRNA #miRNAinhibitor #miRNAmimic